An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
Reads0
Chats0
TLDR
The standard of care (SOC) therapy for patients with chronic hepatitis C virus (HCV) infection has been the use of both peginterferon (PegIFN) and ribavirin (RBV) as mentioned in this paper.About:
This article is published in Hepatology.The article was published on 2011-10-01 and is currently open access. It has received 1117 citations till now. The article focuses on the topics: Boceprevir & Telaprevir.read more
Citations
More filters
Journal ArticleDOI
Therapy of Hepatitis C — Back to the Future
T. Jake Liang,Marc G. Ghany +1 more
TL;DR: Although the introduction of ribavirin combination therapy and pegylated interferons had increased response rates, the real breakthrough came with the development of direct-acting antiviral agents (DAAs) and the first generation of DAAs.
Journal ArticleDOI
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.
Maribel Rodriguez-Torres,Eric Lawitz,Kris V. Kowdley,David R. Nelson,E. DeJesus,John G. McHutchison,Melanie Cornpropst,M. Mader,Efsevia Albanis,Deyuan Jiang,Christy M. Hebner,William T. Symonds,M.M. Berrey,J. Lalezari +13 more
TL;DR: These results support further studies with sofosbuvir at 200 mg and 400 mg to determine the optimal dose and treatment duration of sofOSbuvir in HCV genotype 1.
Journal ArticleDOI
Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate.
Jaimie P. Meyer,Javier A. Cepeda,Johnny Wu,Robert L. Trestman,Frederick L. Altice,Sandra A. Springer +5 more
TL;DR: Though just one-third of HIV-infected prisoners receiving ART entered correctional facilities with viral suppression, HIV treatment was optimized during incarceration, resulting in the majority achieving viral suppression by release.
Journal ArticleDOI
Dried blood spots: a tool to ensure broad access to hepatitis C screening, diagnosis and treatment monitoring
Alexandre Soulier,Lila Poiteau,Isabelle Rosa,Christophe Hézode,Françoise Roudot-Thoraval,Jean-Michel Pawlotsky,Stéphane Chevaliez +6 more
TL;DR: This study shows that whole-blood specimens collected using the DBS technique can be confidently used to diagnose and monitor HCV infection and that HCV genotype determination was possible in the vast majority of DBS.
Journal ArticleDOI
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials.
Patrick Marcellin,Hugo Cheinquer,Manuela Curescu,Geoffrey Dusheiko,Peter Ferenci,Andrzej Horban,Donald M. Jensen,Gabriella Lengyel,Alessandra Mangia,Denis Ouzan,Massimo Puoti,Maribel Rodriguez-Torres,Mitchell L. Shiffman,Manuela Schmitz,Fernando Tatsch,Mario Rizzetto +15 more
TL;DR: AVR by week 2 or 4 had the highest positive PV for SVR24 and differed according to HCV genotype, while the absence of a VR by week 12 had the high negative PV across all genotypes.
References
More filters
Journal ArticleDOI
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Michael W. Fried,Mitchell L. Shiffman,K. Rajender Reddy,C. Smith,George Marinos,Fernando L. Gonçales,Dieter Häussinger,Moisés Diago,Giampiero Carosi,Daniel Dhumeaux,Antonio Craxì,A. Lin,Joseph Hoffman,Jian Yu +13 more
TL;DR: In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferonAlfa- 2b plus Ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interfer on alfa -2b plus ribvirin or pegin terferonalfa-3a alone.
Journal ArticleDOI
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Michael P. Manns,John G. McHutchison,Stuart C. Gordon,Vinod K. Rustgi,Mitchell L. Shiffman,Robert Reindollar,Zachary Goodman,Kenneth Koury,Mei Hsiu Ling,Janice K. Albrecht +9 more
TL;DR: In patients with chronic hepatitis C, the most effective therapy is the combination of peginterferon alfa-2b 1.5 microg/kg per week plus ribavirin, and this randomised trial found that the benefit is mostly achieved in patients with HCV genotype 1 infections.
Journal ArticleDOI
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.
Dongliang Ge,Jacques Fellay,Alexander J. Thompson,Jason Simon,Kevin V. Shianna,Thomas J. Urban,Erin L. Heinzen,Ping Qiu,Arthur H. Bertelsen,Andrew J. Muir,Mark S. Sulkowski,John G. McHutchison,David Goldstein +12 more
TL;DR: It is reported that a genetic polymorphism near the IL28B gene, encoding interferon-λ-3 (IFN-α-2a) is associated with an approximately twofold change in response to treatment, both among patients of European ancestry and African-Americans.
Journal ArticleDOI
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Stephanos J. Hadziyannis,Sette H,Timothy R. Morgan,Balan,Moisés Diago,Patrick Marcellin,G. Ramadori,Henry C. Bodenheimer,David I. Bernstein,Mario Rizzetto,Stefan Zeuzem,Paul J. Pockros,A. Lin,Andrew M. Ackrill +13 more
TL;DR: Treatment with peginterferon-alpha2a and ribavirin may be individualized by genotype, and in patients infected with HCV genotype 1, 48 weeks of treatment was statistically superior to 24 weeks and standard-dose ribvirin was statistically inferior to low-dose Ribavirin.
Journal ArticleDOI
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson,John G. McHutchison,Geoffrey Dusheiko,Adrian M. Di Bisceglie,K. Rajender Reddy,Natalie Bzowej,Patrick Marcellin,Andrew J. Muir,Peter Ferenci,Robert Flisiak,Jacob George,Mario Rizzetto,Daniel Shouval,Ricard Sola,R. Terg,Eric M. Yoshida,Nathalie Adda,Leif Bengtsson,Abdul J. Sankoh,Tara L. Kieffer,Shelley George,Robert S. Kauffman,Stefan Zeuzem,Vertex Phar +23 more
TL;DR: Telaprevir with peginterferon-ribavirin was associated with significantly improved rates of sustained virologic response in patients with HCV genotype 1 infection who had not received previous treatment, with only 24 weeks of therapy administered in the majority of patients.
Related Papers (5)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson,John G. McHutchison,Geoffrey Dusheiko,Adrian M. Di Bisceglie,K. Rajender Reddy,Natalie Bzowej,Patrick Marcellin,Andrew J. Muir,Peter Ferenci,Robert Flisiak,Jacob George,Mario Rizzetto,Daniel Shouval,Ricard Sola,R. Terg,Eric M. Yoshida,Nathalie Adda,Leif Bengtsson,Abdul J. Sankoh,Tara L. Kieffer,Shelley George,Robert S. Kauffman,Stefan Zeuzem,Vertex Phar +23 more